3 recruiting, 1 completed. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ritlecitinib 50 mg: new trials by email Literature Review of Ritlecitinib 50 mg trials Research Report on Ritlecitinib 50 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 336 | 2026-07-30 | 2026-09-10 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-06-17 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
| A Target Occupancy Study With Ritlecitinib. Ritlecitinib 50 mg, Ritlecitinib 200 mg - Healthy | Phase 1 | Completed | Pfizer | 16 | 2021-10-22 | 2023-11-13 |
Alopecia Areata (2) · Alopecia (1) · Alopecia universalis (1) · Chronic Urticaria (1) · Hair Diseases (1) · Pruritus (1) · Urticaria (1)
Pfizer (4)
United States (4) · Canada (3) · Japan (3) · China (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · Bulgaria (1) · Czechia (1) · Germany (1) · Puerto Rico (1) · United Kingdom (1)
2025 (1)